EE+ POEM Archive
Oral semaglutide may reduce mortality in patients with T2DM and known CVD, but confirmation from a larger trial is needed
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Oral Semaglutide May Reduce Mortality in Patients With T2DM and Known CVD, but Confirmation From a Larger Trial Is Needed." EE+ POEM Archive, John Wiley & Sons, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314865/all/Oral semaglutide may reduce mortality in patients with T2DM and known CVD, but confirmation from a larger trial is needed.
Oral semaglutide may reduce mortality in patients with T2DM and known CVD, but confirmation from a larger trial is needed. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2026. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314865/all/Oral semaglutide may reduce mortality in patients with T2DM and known CVD, but confirmation from a larger trial is needed. Accessed July 21, 2026.
Oral semaglutide may reduce mortality in patients with T2DM and known CVD, but confirmation from a larger trial is needed. (2026). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314865/all/Oral semaglutide may reduce mortality in patients with T2DM and known CVD, but confirmation from a larger trial is needed
Oral Semaglutide May Reduce Mortality in Patients With T2DM and Known CVD, but Confirmation From a Larger Trial Is Needed [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2026. [cited 2026 July 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314865/all/Oral semaglutide may reduce mortality in patients with T2DM and known CVD, but confirmation from a larger trial is needed.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Oral semaglutide may reduce mortality in patients with T2DM and known CVD, but confirmation from a larger trial is needed
ID - 1314865
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314865/all/Oral semaglutide may reduce mortality in patients with T2DM and known CVD, but confirmation from a larger trial is needed
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
